Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200156 | 0.85 | GRM5 (0.43) | GRM5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6212636 | 0.85 | GRM5 (0.47) | GRM5ACACBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6198642 | 0.82 | GRM5 (0.50) | GRM5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6198861 | 0.82 | GRM5 (0.44) | GRM5NPC1RAB9AMAPTLMNA | |
| SCHEMBL6200432 | 0.81 | HPGD (0.44) | GRM5ACACBSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6199750 | 0.77 | MAPK1 (0.43) | GRM5SMN1; SMN2RAB9AMAPTLMNA | |
| SCHEMBL6201462 | 0.76 | ADORA3 (0.47) | GRM5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6502589 | 0.76 | FFAR1 (0.41) | GRM5 | |
| SCHEMBL6199786 | 0.76 | GRM5 (0.52) | GRM5SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL6203026 | 0.76 | LMNA (0.48) | GRM5SMN1; SMN2RAB9AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349839-B8 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | claimed |
| EP-1349839-B1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | EP | claimed |
| EP-1349839-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | claimed |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | F.HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | US | claimed |
| WO-2002046166-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | claimed |
| US-6972299-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMANN-LA ROCHE INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-6927232-B2 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | HOFFMAN-LA ROCHE INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1349839-B8 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1349839-B1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | EP | disclosed |
| US-6706707-B2 | TREATMENT OR PREVENTION OF MGLUR5 RECEPTOR MEDIATED DISORDERS. | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | MUTEL VINCENT (FR) | 2003-11-06 | — | — | US | disclosed |
| EP-1349839-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | F.HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002046166-A1 | PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131043-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM6 | GRM5 1/4885ACACB 2767/4885SMN1; SMN2 2192/4885 |
| US-20030208082-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | GRM5 1/4885ACACB 2442/4885SMN1; SMN2 2523/4885 |
| US-20020128263-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, GRM1 | GRM5 1/4885ACACB 2442/4885SMN1; SMN2 2523/4885 |
| US-20030225070-A1 | Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles | GRM5, GRIK5, HRH4 | GRM5 1/4885ACACB 2482/4885SMN1; SMN2 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.